Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Pyoderma Gangrenosum
NCT04901325Phase 2Completed
- Sponsor
- Oregon Health & Science University
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in pyoderma gangrenosum (PG), sponsored by Oregon Health & Science University. Primary endpoint: Healing at 24 weeks. Started Oct 2023; status: completed.
02
Drugs
baricitinib
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT04901325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901325.